Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
UTHealth researcher studies novel cell therapy to prevent GVHD

UTHealth researcher studies novel cell therapy to prevent GVHD

The key to treating AML may lie within FTL3 gene mutations

The key to treating AML may lie within FTL3 gene mutations

Researchers discover new class of molecular mutation in breast cancer

Researchers discover new class of molecular mutation in breast cancer

ALL induction treatment failure should not be an automatic indication for bone marrow transplant

ALL induction treatment failure should not be an automatic indication for bone marrow transplant

Researchers discover a lead on the origin of chronic lymphatic leukaemia

Researchers discover a lead on the origin of chronic lymphatic leukaemia

FDA grants Fast Track designation to EpiCept's AmiKet

FDA grants Fast Track designation to EpiCept's AmiKet

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

Novel approach to kill acute lymphoblastic leukemia cells

Novel approach to kill acute lymphoblastic leukemia cells

Feinstein scientists to present three GBM abstracts at AACR annual meeting

Feinstein scientists to present three GBM abstracts at AACR annual meeting

Bio-Path 2011 net loss increases to $2,363,344

Bio-Path 2011 net loss increases to $2,363,344

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Safe method for destroying cancer cells using death cap mushroom poison

Safe method for destroying cancer cells using death cap mushroom poison

Targeting inflammatory pathways may lead to new therapies

Targeting inflammatory pathways may lead to new therapies

Inovio awarded U.S. DOD grant to advance non-invasive surface electroporation delivery device

Inovio awarded U.S. DOD grant to advance non-invasive surface electroporation delivery device

Blocking PRC2 protein may help protect against AML

Blocking PRC2 protein may help protect against AML

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Study provides new information on why A-T disease attacks the brain

Study provides new information on why A-T disease attacks the brain

Scientists identify potential drug target for mixed lineage leukaemia

Scientists identify potential drug target for mixed lineage leukaemia

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

Change in registry protocols leads to underreporting of myeloid malignancies

Change in registry protocols leads to underreporting of myeloid malignancies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.